Evidence map›Paper›PMID 40964107›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[TruScreen Combined With High-Risk Human Papillomavirus Testing vs Thinprep Cytology Test Combined With High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: A Comparative Clinical Study].

Yi Yang, Chunmei Li, Shuyun Jia, Yifeng Wang, Dengpan Wang, Liyin Zhang

Abstract readComparative StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi Yang（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.ORCID 0009-0008-9055-6913
Chunmei Li（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.
Shuyun Jia（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.
Yifeng Wang（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.
Dengpan Wang（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.
Liyin Zhang（） （ 617000） Department of Gynecology, Panzhihua Central Hospital (The Second Clinical Medical College of Panzhihua University), Panzhihua 617000, China.ORCID 0009-0005-3146-5665

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the clinical value of TruScreen, an artificial intelligence-based real-time cervical cancer screening system, combined with high-risk human papillomavirus (hr-HPV) test and Thinprep cytology test (TCT) combined with hr-HPV test in cervical cancer screening. Methods: A total of 297 women undergoing cervical cancer screening at Panzhihua Central Hospital between June 2020 and December 2023 were enrolled. All participants underwent hr-HPV testing, TCT, and TruScreen test. The diagnostic performance of TruScreen combined with hr-HPV test and TCT combined with hr-HPV test for low-grade squamous intraepithelial lesion positive (LSIL Results: Among the 297 enrolled women, pathology analysis identified 128 (43.10%) LSI Conclusion: TruScreen combined with hr-HPV test demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test. TruScreen combined with hr-HPV test may serve as an alternative to conventional cytology-based methods for cervical cancer screening in China.

Indexed as

Early Detection of CancerPapillomaviridaePapillomavirus InfectionsUterine Cervical NeoplasmsAdultAgedArtificial IntelligenceFemaleHuman Papillomavirus VirusesHumansMiddle AgedUterine Cervical DysplasiaVaginal SmearsArtificial intelligenceCervical cancer screeningCervical neoplasmsHigh-risk human papillomavirusThinprep cytology test

Identifiers

PMID40964107
PMCPMC12439646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.